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The antibody present in some instances when thrombocytopenia is due to 
drug  sensitivity not  only fixes complement in  the presence of platelets  and 
the  offending drug,  but  also  agglutinates  platelets  and  acts  to  inhibit  clot 
retraction (1-4). It has been considered that the antibody also lyses platelets 
in the presence of complement (4). The antibody has been suspected of acting 
on endothelium (1, 3),  and in one report (5)  the antibody present following 
thrombocytopenia due to quinidine was found to fix complement with red cells 
and cause their agglutination and lysis. 
In the present work,  the activity of the antibody as a  platelet agglutinin 
was compared with its activity in complement-fixing reactions, the nature of 
morphological changes in platelets in the presence of antibody and quinidine 
was studied, and some aspects of inhibition of clot retraction by the antibody 
were  investigated.  Observations  were  also  made  concerning  specificity and 
other  qualitative  properties  of  the  antibody.  The  studies  were  directed  at 
determining interrelationships of the different antibody activities, the relative 
sensitivity  of various  quantitative  and  qualitative  tests  for the presence of 
antibody, and possible factors of significance in the pathogenesis of thrombo- 
cytopenic purpura due to drugs. 
Materials and Methods 
All reagents, the source of antibody, and methods of measuring complement fixation and 
determining antibody units were the same as in Paper I. 
Measurement of Platdet Agglutenation.--Siliconed glassware was used throughout and ob- 
servations were made at room temperature. Mixtures of platelet suspensions prepared as in 
Paper I, patient's  serum containing antibody, and quinidine were made in  12 X 75 ram. 
test tubes; and aliquots were transferred immediately to slides and overlaid with coverslips 
ringed with vaseline to permit prolonged microscopic  observation of the wet preparations. 
Agglutination occurred equally well in slide preparations and in aliquots remaining in the 
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tubes. All sera in agglutination  mixtures were heated at 56  ° for 40 minutes before use unless 
otherwise indicated.  Only those platelet  suspensions which remained  morphologically unal- 
tered and did not show non-specific agglutination for long periods at room temperature  were 
considered satisfactory  for agglutination  tests.  When  antibody was  titrated,  dilutions  of 
patient's serum with serum from normal individuals gave the same results as dilutions with 
saline. Preliminary mixing of any two reagents 1 hour before adding the third had no effect 
on the degree of agglutination or the rate at which it occurred. 
Measur~nent of Clot Retraction.--Mixtures of 3 ml. of whole blood with 0.2 ml. of test solu- 
tion, made in siliconed graduated test tubes, were allowed to clot spontaneously or were clotted 
with  10 units  of thrombin  (Parke,  Davis & Company) with 0.1 ml. of saline. Spontaneous 
clotting occurred in approximately 30 minutes in the siliconed tubes; clotting after addition 
of thrombin  took place within 30 seconds. Applicator sticks used for mixing reagents were 
left in the tubes. After the tubes were incubated  1 hour at 37  °, the applicator sticks with ad- 
herent clots were removed and the volume of free fluid plus ceils not incorporated in the clots 
was measured. Using normal blood, the volume of free serum and cells following spontaneous 
coagulation or clotting with thrombin was 54 4- 5 per cent of the original volume of blood 
used. The technique is similar to one used by Luda et al. (6). 
EXPE~r~f~.NTS  AND  RESULTS 
1.  Agglutination Reactions.~ 
(a)  Effect  of antibody  concentration  on  platelet  agglutination.  The  effect  of 
varying the concentration of antibody on the degree of platelet  agglutination 
is  shown  in  Table  I,  using  the  criteria  for  grading  agglutination  shown  in 
Fig.  1.  The concentration  of antibody  which  produced  1+  agglutination  in 
1 hour had to be approximately doubled to produce 2+  agglutination,  quad- 
rupled  to produce 3+  agglutination,  and increased  eightfold to produce 4+ 
agglutination.  The rate  of development  of agglutination  as  well  as  the  final 
degree  of agglutination  reflected  antibody  concentration.  Agglutination  pro- 
gressed  with  time after  the  1 hour interval  chosen for the final reading; e.g., 
mixtures showing 1+  agglutination at 1 hour would show as much as 2+  and 
occasionally 3+  agglutination after  16 hours, and some mixtures showing no 
agglutination  at  1  hour would show  4-  or  1+  agglutination  after  16 hours. 
Observations were limited to the 1 hour period when quantitative comparisons 
of results  were attempted  because beyond that interval visible differences  in 
agglutination with large changes in antibody concentration were less definite, 
and  control mixtures  completely free of agglutination  were more difficult  to 
obtain. 
The concentration of platelets in an agglutination mixture affected the degree 
of agglutination obtained when antibody concentration was constant. Increas- 
ing platelet  concentrations resulted in smaller aggregates of platelets until no 
agglutination  occurred,  and  decreasing  platelet  concentrations  limited  the 
ability to differentiate  degree of agglutination  based on size of platelet  aggre- 
gates. In order to compare changes in degree of agglutination, platelet concen- 
tration had to be kept constant.  The platelet concentration found to be most 
suitable  for reading  agglutination  and  which was used as routine  was  2.5  × 
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The  approximate titer of antibody in a  serum sample could  be measured 
by the highest final dilution of serum producing  1-b agglutination in 1  hour. 
The titer was only as precise as the range of dilution giving little detectable 
difference in degree of agglutination; e.g.,  1/~o to ~o  dilution for serum con- 
talnlng a high concentration of antibody, or ~  to ~  dilution for serum with ~0 
that  concentration  of  antibody.  By  comparing  agglutination  titer  with  the 
concentration of antibody in units/milliliter determined as in Paper I, it was 
TABLE I 
E.ffeet of Antibody Concentration on Platde~ A gglugnagon 
Tubes contained 0.05 ml. quinidine gluconate (10 mg./ml.),  0.05 ml. platelets  (2.5 X 
106/mm.3), varying amounts of serum, and saline to bring the final volume to 0.5 ml. Final 
quinidine concentration, 10  -~'7~ K; final platelet  concentration, 2.5 X  10~/mm.3; reciprocal 
of final serum dilutions as tabulated.  Undiluted serum contained 200 units  of antibody/ 
ml.  determined  as  in  Paper  I.  Incubated  at  room  temperature;  degree of  agglutina- 
tion graded as shown in Fig. 1. Control mixtures, containing all reagents except for quini- 
dine or all reagents with normal serum substituted  for patient's serum, showed no agglu- 
tination. 
Serum dilution 
(reciprocal) 
1.25 
1.67 
2.50 
5.0 
6.0 
10.0 
13.3 
20.0 
30.0 
40.0 
80.0 
¢O 
Antibody 
uni~/ml. 
120 
~.3 
20.0 
15.0 
10.0 
6.7 
5.0 
2.5 
0 
15 rain. 
4+ 
4+ 
2+ 
1+ 
1+ 
1+ 
4- 
4- 
o 
o 
o 
0 
Degree of agglutination 
30 rain. 
4+ 
4+ 
3+ 
2+ 
2+ 
1-2+ 
1+ 
1+ 
q- 
4- 
o 
o 
mha. 
4+ 
4+ 
3-4+ 
3+ 
3+ 
2+ 
2+ 
1-2+ 
1+ 
4--1+ 
0 
0 
60 min. 
4+ 
4+ 
4+ 
4+ 
3-4+ 
3+ 
2-3+ 
2+ 
1+ 
1+ 
0 
0 
found that 1-b agglutination occurred in the presence of 4 to 6 units of anti- 
body/ml, when quinidine concentration was optimal. If the incubation period 
was extended  to  16 hours,  -4-  or  1+  agglutination  occurred  when  antibody 
concentration was 2 to 3  units/ml.,  and this was the order of antibody con- 
centration which could be detected qualitatively by agglutination techniques. 
(b) Effect  of quinidine  concentration  on platelet agglutination.  Table II shows 
changes in  degree of agglutination  when  quinidine  concentration was varied, 
using several different concentrations of antibody. The higher the concentra- 
tion of antibody, the lower the concentration of quinldine at which agglutination 
could be measured. If a  16 hour incubation time was used instead of the stand- 
ard 1 hour period, q- to 1-b agglutination occurred at a  quinidine concentra- 700  EWMUNO]LEACTIONS  INVOLVING  PLATELETS.  III 
tion 0.7 to 1.0 decade on a log scale below the lowest quinidine concentration 
giving  1+  agglutination  with  each  amount  of  antibody  in  Table  II.  At 
the lower concentrations of antibody, less agglutination occurred when quini- 
dine concentration was very high (10  -1.s~ ~r) than at quinidine concentrations 
giving maximum agglutination. 
2.  Morphological Changes in Platelets Exposed to Antibody  and Quinidine.-- 
Ackroyd considered that  the  antibody of sedormid  purpura  acted  as  an 
agglutinin  in  the  absence  of complement and as  a  lysin in  the  presence of 
TABLE II 
Effect of Quinidine Concentratio~ on Platelet Agglutination 
Conditions as in Table I with final quinidine concentration and final antibody concentra- 
tion as tabulated. Degree of agglutination observed after incubation for 1 hour. 
Degree of agglutination 
Quinidine 
gluconate log x  Final antibody concentration units/ral. 
concentration 
150  50  25  12.5  6.25 
--1.82" 
--1.945 
--2.72 
--3.72 
--4.72 
--5.34 
-5.72 
-6.04 
-6.72 
-7.72 
4+ 
4+ 
4+ 
4+ 
4+ 
4+ 
3+ 
1+ 
4- 
0 
4+ 
4+ 
4+ 
4+ 
4+ 
3+ 
1+ 
0 
0 
2-3+ 
3+ 
3+ 
3+ 
3+ 
2+ 
1+ 
0 
1+ 
2+ 
2+ 
2+ 
1+ 
0 
1 
m 
o 
1+ 
i-I- 
1+ 
o 
* A profuse precipitate with particles showing Brownian motion occurred in these tubes. 
~: Moderate amount of clumped precipitate present in these tubes. 
complement (4). The following observations suggest that the antibody may not 
necessarily act directly as a platelet lysin in association with complement. In the 
usual  agglutination  mixture  platelets  occasionally  became  less  refractile, 
swollen,  and misshapen,  the over-all morphological change perhaps best  de- 
scribed as "fading," for they did not completelylose  their identity. If fading did 
occur, it took place either before, during, or after the development of aggluti- 
nation. With  any one platelet preparation, fading either did not occur when 
platelets were agglutinated (e.g. Fig. 1) or occurred regardless of the degree of 
agglutination. If fading was observed, it was either slight or marked but of the 
same degree in mixtures containing insufficient antibody or quinidine to cause 
agglutination as well as enough to cause 4-}- agglutination; whereas the same 
platelets  in  control  mixtures  remained  morphologically  intact.  Fading  of N. RAPHAEL  SIiuLMAN  701 
platelets was frequently seen when  the patient's native serum was used  as a 
source of antibody in agglutination mixtures and was less frequently seen when 
the patient's native plasma was  used.  It did occur,  however,  in mixtures in 
which serum or plasma as the only source of complement had been heated at 
56  ° for 40 minutes immediately before use. 
TABLE III 
Inhibition  of Clot Raraction  by Quinidine  in the Presence and Absence of Antibody 
Tests carried out as described in Materials and Methods. Whole blood was used but 
qulnidine concentration is expressed per milliliter of plasma; patient's hematocrit value 42 
per cent, that of normal blood sample 44 per cent. Tabulated results of per cent free fluid are 
the average of two determinations. Patient's blood contained 10.5 units of antibody/mL of 
plasma. A final plasma concentration of 0.036 M Na citrate was obtained by adding 0.2 mL 
of 0.36 M Na citrate to the clotting mixtures. When thrombin was used for clotting it was the 
last reagent added. Inhibition of clot retraction could be considered  complete when  10 per 
cent or less free  fluid was obtained. 
Blood containing antibody  Normal blood 
10.5 units/ml, plasma 
Clot retraction; per ce~t free fluid 
Quinidine 
gluconate 
concentration 
mg./ral,  log x 
0  0 
0.0015  -5.54 
0.005  --5.02 
0.01  --4.72 
0.05  --4.02 
0.1  --3.72 
0.15  --3.54 
0.2  --3.42 
Spon- 
taneous 
coagula- 
tion 
51 
48 
25 
24 
18 
14 
5 
4 
Clotted 
with 
thrombtn 
52 
49 
20 
22 
15 
9 
5 
6 
Clotted with 
thrombln in 
presence of 
0.036MNa 
citrate 
i 
m 
54 
49 
53 
50 
I 
Quiuidlne gluconate 
concentration 
~g./m:. [  ~g x 
0  I 
1.1  I --2.68 
1.31--2.61 
1.5  --2.54 
t.9  --2.43 
L2  --2.38 
2.51--2.32 
3.01--2.24 
3.5!--2.18 
4.0  i  -2.12 
Clot retraction; 
per cent free fluid 
Clotted with 
SPOn-  thrombin in  taneous  presence of 
coagula-  0.036 K Na 
tion  citrate 
54 
58 
52 
45 
39 
24 
23 
15  17 
11  8 
6  7 
3.  Inklbition  of Clot Retraction.- 
The effect of quinidine concentration on degree of inhibition of clot retraction 
of blood containing antibody and normal blood is shown in Table III. Quinidine 
inhibited clot retraction of normal blood detectably when the plasma conten- 
t.ration  was  approximately  10  -~.~ x~  (1.5  rag.  quinidine  gluconate/ml.)  and 
completely  when  the  concentration  was  approximately  10  --~.xs •  (3.5  rag. 
quinidine gluconate/ml.); whereas inhibition of clot retraction of the patient's 
blood containing 10.5  units of antibody/ml, of plasma was detectable at con- 
centrations of quinidine between  10  -s.4 and  10  -~ M and complete at approxi- 702  TM-MUNO1LEACTIONS  INVOLVING  ]PLATELETS.  HI 
mately  10  -s.r  ~r  quinidine.  Tests  done  with  blood  containing different  con- 
centrations of antibody showed that an inverse relationship existed between the 
concentration  of  antibody  and  the  concentration  of  qulnidine  required  to 
produce  detectable  and  complete  inhibition  of clot  retraction.  The  units  of 
I.  2.  3.  4.  5. 
6.  Z  8.  9.  I0. 
•  rg~-Fm. 1. Inhibition  of clot retraction  using citrate-plasma.  Experimental  tubes (1 to 
5) contained 0.4 ml. of varying dilutions of patient's heated  serum in normal heated serum, 
0.02 ml. 10  -z ~s quinidine gluconate, 0.2 ml. platelet-rich citrate-plasma  (10  s platelets/mm)), 
1.35 cal. plateht-free citrate-plasma, and 0.03 nd. of thrombin solution containing 10 units of 
thrombin.  Undiluted patient's serum contained  150 units antibody/ml. Citrate-plasma  con- 
talned  0.046 molar  citrate.  Final  concentrations:  quinidine,  10  -s  ~s;  platelets,  10~/mm.a; 
citrate,  0.036 ~r; antibody,  tube No. 1 ffi 30 units/ml.,  No. 2 -- 15 units/inf.,  No. 3 -- 7.5 
units/mL,  No. 4 ffi 4 units/mL,  and No. 5 ffi 2 units/ml. Control tubes (6 to 10) contained 
0.4 ml. of heated normal serum, 0.02 ml. 10-1 ~s quinidine glueonate, 1.55 ml. of varying dilu- 
tions of platelet-rich citrate-plasma in platelet-free citrate-plasma, and 0.03 ml. of thrombin. 
Final concentrations:  quinidine, 10  -a  ~s;  no  antibody;  platelets,  tube No.  6--0.625 X 
104/ram. s, No.  7  :  1.25  X  104/mm), No. 8  :  2.5  X  104/mm. s, No. 9  :  5  X  104/ram. 8, and 
No. 10 ffi 10 X  104/ram#. 
The method  of measuring clot  retraction  is similar  to one described by Hartmann and 
Conley (8). 
antibody required for m~nimal and complete inhibition of clot retraction were 
determined using a plasma quinidine concentration of 10  -*'72 ~r (1 mg. quinidine 
gluconate/ml,  plasma),  a  concentration  which  was  optimal  for  complement 
fixation and agglutination reactions but which did not inhibit clot retraction of 
normal blood. With this concentration of quinidine complete inhibition of clot 
retraction occurred in patient's blood when antibody concentration was as low 
as  approximately  5  units/ml,  plasma,  partial  inhibition  occurred when  anti- N.  RAPHAEL SHULMAN  703 
body concentration was from 2.5 to 3.5 units/ml., and no inhibition occurred 
when antibody concentration was less  than approximately 2.0 units/ml. The 
minimum concentration of antibody which could be detected with certainty 
using this technique was in the order of 2 to 3 units/ml, of plasma. These data 
were obtained using whole blood of  patients during the rise and decline of 
antibody concentration following test doses of quinidine (see Paper IV). 
Although inhibition of clot retraction could be produced in normal whole 
blood or in a  test system consisting of platelets suspended in normal citrate- 
plasma by adding patient's serum or plasma containing antibody along with 
quinidine, the amount of antibody added could not be titrated accurately in this 
manner. For example, although partial inhibition of clot retraction was pro- 
duced by adding the patient's serum to a system containing 105 platelets/mm? 
and 10  -~ x~ quinidine in citrate-plasma, complete inhibition was not obtained 
even when the final antibody concentration in the mixture was as high as 30 
units/m1.  (Text-figure  1).  Similarly,  transferring  antibody in  the  form  of 
patient's serum to normal whole blood did not produce the degree of inhibition 
of clot retraction expected from the final concentration of antibody in  the 
mixture. 
Failure of transferred antibody to produce the expected degree of inhibition 
of dot retraction in the test systems used was related in one case (see Table HI, 
also reference 2)  to  the presence of citrate  1 which partially interfered with 
inhibition of clot retraction, and in the other case possibly to some non-specific 
effect of serum itself when present prior to initiation of coagulation. 
4.  Specificity of Antibody Reactions.-- 
(a) Homologous platelets. Antibody in the presence of qnlnidine agglutinated 
the patient's own platelets and the platelets of 30 other individuals to an equal 
degree regardless of their blood group or Rh factor, the patient's blood group 
being Type O, Rh-positive. The patient's platelets and those from individuals 
of all blood groups were equally effective in complement-fix4ng reactions. A 
possibility existed that platelets from individuals taking quinidine might differ 
from normal platelets, perhaps  by containing more firmly bound quinidine. 
Two normal donors were given 0.2 gln. quinidine sulfate every 8 hours for 4 
days; blood was drawn 2 hours after the last dose of quinldine; and sedimented 
platelets from 25 ml. of platelet-rich plasma from each donor were washed once 
with 5 ml. of saline. These platelets did not fix complement in the presence of 
I The  anticoagulant, disodium salt  of  ethylenediaminetetraacetic add  (sequestrene), 
when substituted for citrate in a system containing plasma or whole blood for evaluating 
clot retraction, was found to completely  inhibit clot retraction of its own accord; and there- 
fore could  not be used. Inhibition of dot retraction by sequestrene  was not due to a permanent 
effect on platelets (if due to an effect  on platelets at all), for platelets exposed to 0.15 per cent 
sequestrene solution retained their clot-retracting  properties when sequestrene was removed 
by washing  with ~llne. 704  rMMUNOREACTIOlqS INVOLVING  PLATELETS.  III 
antibody unless quinldine was added to the complement-fixing  mixture,  and 
then their activity was the same as normal platelets. There was no evidence 
that quinidine was bound more firmly by platelets in vivo than by platelets in 
vitro (see Paper I). 
(b) Heterologous platelets. The platelets of 8 dogs, ? rabbits, 4 rhesus monkeys, 
and 4 guinea pigs were not agglutinated in the presence of amounts of antibody 
and quinidine  which produced 4+  agglutination  with human platelets when 
the same techniques for preparing  platelet suspensions  and performing tests 
were used. Platelets from the rabbits gave 1-2+ agglutination in both control 
UNITS  ~  ~o  o///o\ 
PLATELET_  2  4  "  6 
CONC. X I0 
TExT-FIG. 2. Comparison of effectiveness of human and monkey platelets in complement- 
fixing reactions. Reactions carried out as in Paper I, Fig. i. Antibody concentration 2.3 units/ 
0.5 ml. mixture and quinidine concentration  I0  --2'9 ~¢ in each case.  Similar results were ob- 
tained with platelets from two other monkeys. 
tubes and  tubes containing  quinidine.  Platelets  from all  the animals  except 
monkeys did not fix complement or adsorb antibody when tested using a range 
of platelet concentrations  as  in  Paper  I,  Fig.  1.  Although  rhesus  monkey 
platelets  were  not  agglutinated,  they  were  effective  in  complement-fixing 
reactions  and  adsorbed  antibody.  The  concentration  of  monkey  platelets 
required to completely adsorb a given amount of antibody was approximately 
3 times that of human platelets. The difference in effectiveness of monkey and 
human platelets in complement-fixing  reactions is shown in Text-fig.  2.  The 
amount of quinidine adsorbed by monkey, dog, and rabbit platelets incubated 
in q,]inidine  solutions as in Paper I, Table III, was similar in each case to the 
amount adsorbed by human platelets. 
(c) Endothelial cells. It was considered by Ackroyd that a reaction between 
antibody and endothelium may account in part for hemorrhagic manifestations 
of drug purpura.  In one report (9) ground choroid plexus did not fix comple- N.  1L4~PIIA~L  SB.~ULMAN  705 
ment in the presence of the antibody of quinidine purpura and quinidine,  and 
did not adsorb antibody. In the present experiment intact endothelial cells were 
used in the same manner  as platelets in an attempt to fix complement and 
adsorb antibody. 
The endothelial lining of a section of human aorta obtained at autopsy 5 hours after death 
was scraped off with a knife blade and the membranous material was minced and  washed 
twice with saline. The small sheets of cells obtained had characteristic endothelial morphology 
(Fig. 1 F). These cells in saline suspension were added to complement-fixing  mixtures con- 
taining 40 units of antibody and 10  -~.9 v  quinidine. The mounts of endothelial ceils added 
were equivalent in dry weight to amounts of platelets covering a suboptimal, optimal, and 
above optimal range of platelet concentrations for this concentration of antibody (see Paper I, 
Fig. 1), the dryweight of 10a platelets being 3.2 mg. 
Under  these conditions  endothelial cells did not fix complement or  adsorb 
antibody. 
(d) grythrocfles. An instance in which an antibody associated with  thrombo- 
cytopenia due to quinidine fixed complement in the presence  of the  drug and 
red cells has been reported (5) but corresponding in vitro tests with platelets were 
not presented. Plain washed red cells and red cells  treated  with trypsin (10), 
both  from  the  patient  and  from  donors,  were  used  in  complement-fixing 
mixtures, the range of concentration of red cells used being similar to  that  of 
platelets in Paper I, Fig.  1. In no case was complement fixed or  antibody  ad- 
sorbed, and the red cells remained morphologically intact and did not aggluti- 
nate in the mixtures. 
(e) Cinchona alkaloids. Just as in the case of  complement-fixing  reactions, 
cinchonine could be substituted for quinidine at the same molar concentrations 
for agglutination reactions and for inhibition of clot retraction whereas quinine 
and cinchonidine were ineffective. 
(f) Passive anapkylaxis. 
Four guinea pigs weighing approximately 450 gin. were injected intravenously with 320 
units of antibody contained in 2 ml. of heated (56  ° for 30 minutes) patient's serum. Two days 
later two of the guinea pigs were injected intravenously with 101° platelets mixed with 8 rag. 
of quinidine gluconate in a volume of 2.5 ml.; and the other two were injected first with 10  ~ 
platelets followed 1 hour later by 8 rag. of quiuidine gluconate. 
None of the guinea pigs developed any symptoms or elevation in temperature 
suggestive of an anaphylactic reaction. 
DISCUSSION 
Comparison of Agglutination and Complement-Fixing Reactions.--In Paper I, 
Fig. 6, it was shown that the amount of antibody adsorbed per platelet when 
quinldine  concentration was  10  -e'x° ~t was approximately 25 per cent of that 
adsorbed when quinidine  concentration was optimal although no complement 
fixation  could  be  measured  at  the  suboptimal  quinidine  concentration.  At 706  rM7tcUNOREACTIONS  INVOLVING  PLATELETS.  HI 
10--5.~ ~r quinidine, 50 per cent of the maximum amount of antibody adsorption 
occurred but complement fixation  was only 20 per cent of the maximum. It 
appeared that decreases in  complement fixation  at low quinidine concentra- 
tions were more marked than decreases  in the amount of antibody adsorbed be- 
cause of changes in  the proportion of quinidine in  the antibody-quinidine- 
platelet complex (see Paper I). If degree of agglutination was related only to the 
amount of antibody adsorbed per platelet, a  higher degree of agglutination 
might have been expected when quinidine concentration was in the range of 
10  -5"~ to 10  -6'~ M, particularly with the higher concentrations of antibody (see 
Table II). It appeared likely, therefore, that agglutination as well as comple- 
ment fixation was dependent on the proportion of qulnidine in the complex. 
This possibility was also suggested by the decrease in agglutination observed at 
a high quinidine concentration (10  -x-~ ~) which had been shown in Paper I to 
produce a decrease in complement fixation with no decrease in the amount of 
antibody adsorbed per platelet. Results of agglutination experiments at high 
quinidine concentration may be  open  to  different interpretation,  however, 
because the heavy precipitate which occurred in mixtures containing 10  -1.m M 
quinidine may possibly have interfered with agglutination. 
Antibody activity could be measured accurately by complement fixation 
when antibody was present at concentrations in the order of 0.2 units/ml, and 
could be detected by platelet agglutination and inhibition of clot retraction 
when antibody was present at concentrations in the order of 2 to 3 units/ml. 
Complement fixation was at least 10 times more sensitive than platelet agglu- 
tination or inhibition of clot retraction for measurement of antibody activity. 
Significance of Changes in  Platelet Morpkology.--The  data  presented  by 
Ackroyd in favor of the hypothesis that the antibody acts to lyse platelets in the 
presence of complement is  not  contradicted by the  observations described 
above. In interpreting the present data, however, it appears that there is equally 
good evidence that antibody does not lyse platelets directly in the presence of 
complement but that attachment of antibody to platelets makes them more 
susceptible  to morphologic alteration by non-specific factors in vitro. 
The same morphological changes which could occur in the presence of anti- 
body and quinidine with platelet  preparations  which remained unaltered in 
control mixtures, were occasionally observed without antibody and quinidine in 
suspensions of platelets in plain saline, heated serum, or plasma.  Instability of 
platelets in such suspensions appeared to be related to conditions which favored 
production  of  active  coagulation  factors  during  the  process  of  separating 
platelets from blood, such as unusually slow bleeding of donors,  delayed mixing 
of anticoagulant, or insufficient washes for complete removal of plasma pro- 
teins from platelets. The fact that washing platelets in an anticoagulant (1 per 
cent ammonium oxalate) resulted in unusually stable platelet suspensions  and 
that stable platelets suspended in the presence of even trace amounts of plain N.  RAPHAEL SHIYLMAN  707 
native serum frequently developed morphological changes identical with those 
produced  in  the  presence  of  antibody  and  quinidine  suggested  that  active 
coagulation factors, which in trace amounts are known to alter platelet  mor- 
phology (7),  may account for the  occasional instability  of platelets  in plain 
suspension. Platelets exposed to antibody and quinidine may have become more 
susceptible  to morphologic alteration by trace amounts of coagulation factors 
or other as yet unknown factors which cause instability of platelets in suspend- 
ing media. If such factors were not present in vivo, it is conceivable that morpho- 
logic instability  (or lysis)  of platelets  would not occur in association with at- 
tachment of antibody.  It may be that attachment of antibody to platelets in 
v/go does not result directly in their  destruction but alters  them in a  manner 
which predisposes  to sequestration  from the  circulation  by the  usual  physi- 
ologic processes. 
The  Nature  of Inhibition  of Clot  Retraction.--Because  quinidine  alone  is 
capable of inhibiting clot retraction of normal blood, and in view of the possi- 
bility that qlJinidine attaches first to antibody (see Paper I), it might be argued 
that inhibition of clot retraction which occurs at comparatively low quinidine 
concentration in the presence of antibody may be due to augmented attachment 
of quinidine to platelets in association with antibody, quinidine  then acting to 
inhibit clot retraction as it does in normal blood. 
Calculations made from data of Table III of this paper concerning the concentration  of 
qninidine required to inhibit  clot retraction  of normal blood, and from Table LII of Paper I 
concerning the amount of quinidine adsorbed by plain platelets suspended in qninidine sdu- 
tion indicate that the amount of qninidine adsorbed by 1 ml. of platelets at a concentration 
of 3.0 X  105/mmY  in the presence of a qninidine concentration which inhibits dot retraction 
in normal blood is in the order of 10  ~  mole. The amount of antibody required for association 
with this much quinidine, assuming an average antibody valence of 2 (see Paper I) and an 
M.W. of 100,000, would be 0.5 reg./m1. Of the 10.5 units of antibody/ml, present in inhibition 
of clot retraction  tests in Table III, approximately 30 per cent would be adsorbed by platelets 
at a  concentration  of 3 X  10s/ram.  8 (see Paper I). Therefore  10.5 units of antibody/ml. 
would be equivalent to approximately  1.5 mg. of antibody/ml. Since antibody concentration 
in one patient was as high as 300 units/ml.,  (see Paper IV, Fig. 2), this would imply that the 
amount of antibody in the patient's serum had been as high as 45 mg./ml, which is too high to 
be consistent with known antibody levels (11). Furthermore,  a serum electrophoretic pattern 
obtained when antibody concentration was 50 units/hal, showed no increase in gamma globu- 
lin although  from the above  calculations  antibody would have accounted  for 12% of the 
total proteins.  Any reasonable increase in assumed valence of antibody or decrease in as- 
sumed M.W. would not sufficiently reduce the discrepancy between the calculated and usually 
observed concentrations of antibody. If platelets adsorbed much less quinidine when in plasma 
than when in saline owing to competition for qninidine by plasma proteins,  the possibility 
that inhibition  of clot retraction  is due primarily  to the amount of qninidine attached to 
platelets  (with or without antibody)  could still be considered. However, it was found that 
0.036 ii Na citrate prevented  inhibition  of clot retraction  caused by 10  -3-4s ~  quinidine in 
blood containing antibody but did not interfere with inhibition  of clot retraction  caused by 
much higher qninidine concentrations in normal blood (Table III). Interference with inhibi- 
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onto platelets, for platelets  were  found  to adsorb the same mount of antibody at 10-~ M 
quinidine in the presence and absence of 0.056 M Na citrate. 
Therefore  inhibition  of  clot  retraction  in  the  presence  of  antibody  and 
quinidine and inhibition of clot retraction of normal blood by quinidine alone 
appear to be due to different mechanisms. 
Inhibition of clot retraction was considered by Ackroyd to be due to lysis of 
platelets by the action of complement, and the evidence he presented in favor of 
this hypothesis is substantial (2). However, in the present study, it was found 
that inhibition of clot retraction did not occur in fresh whole blood when anti- 
body concentration was below 2 units/ml, of plasma in spite of the fact that 
much complement was fixed in  vitro  at  this  concentration  of antibody  (see 
Paper I); and it could occur in mixtures in which  citrate concentration  was 
completely  anti-complementary  (Text-fig.  1).  Morphologic  alteration  of 
platelets per se does not necessarily imply that they will not cause clot retrac- 
tion, for disruption of platelets is generally considered to be an integral part of 
the blood coagulation process (7, 12). It is worthy of note that suspensions  of 
platelets  exposed to  concentrations  of antibody  and  quinidine  suificient  to 
completely inhibit  clot  retraction  in  whole  blood  retained  their  ability  to 
promote clot retraction when added to platelet-free plasma after antibody and 
quinidine had been removed from them  by washing with saline.  The  mecha- 
nism of inhibition of clot retraction would appear to be still open to speculation 
as is the process of clot retraction itself (13, 14). The apparent interaction be- 
tween platelets and fibrin which leads to clot retraction may be interfered with 
by the presence of antibody on platelets per se and not by subsequent instabil- 
ity of platelets. 
Specificity of Antibody  Activity.--Of  the various cells tested, the only ones 
which  could  be  substituted  for  human platelets in antibody reactions were 
rhesus monkey platelets. The finding  that monkey platelets did not adsorb as 
much  antibody  or  fix  as  much  complement  as  human  platelets  indicated 
that monkey platelets contained fewer sites per platelet for attachment of anti- 
body and perhaps, in addition, a different arrangement of sites permitting less 
complement to be fixed by attached antibodies (see Paper I). Such factors might 
also account for the inability of monkey platelets with adsorbed antibody to 
agglutinate. Other animal platelets tested gave no evidence of having any sites 
for attachment  of antibody but did adsorb the same amount of quinidine as 
human platelets. The ability of platelets to adsorb large amounts of quinidine 
had no bearing on their ability to enter into reactions with the antibody. 
Quantitative aspects of platelet agglutination and inhibition of clot retraction 
by the antibody of quinidine purpura were described. The reactions appeared to N.  RAPHAEL StiuLMAN  709 
depend on formation of types of antibody-quinidine-platelet complexes which 
could fix complement but complement was not necessary for these reactions. 
Complement fixation was at least 10 times more sensitive than platelet agglu- 
tination  or  inhibition of  clot  retraction  for  measurement  and  detection  of 
antibody activity. 
Although it has been  considered  that  antibodies of drug purpura  act  as 
platelet lysins in the presence of complement and that direct lysis of platelets 
accounts for development of thrombocytopenia in drug purpura,  the present 
study  suggests that attachment of antibody produces a change in platelets which 
is manifested in vitro  only by increased susceptibility to non-specific factors 
which can alter the stability of platelets in the absence of antibody. The at- 
tachment of antibody to platelets in d~o may only indirectly affect platelet 
survival. 
In contrast to human platelets, dog, rabbit,  and guinea pig platelets, and 
normal or trypsin-treated human red cells did not agglutinate, fix complement, 
or adsorb antibody; and intact human endothelial cells did not fix complement 
or adsorb antibody. 
Rhesus monkey platelets were not agglutinated by the antibody but did ad- 
sorb  antibody and fix complement although their activity in these reactions 
differed quantitatively from that of human platelets. 
Cinchonine could be substituted for quinidine in agglutination and inhibition 
of clot retraction reactions but quinine and cinchonidine could not. 
Attempts to cause passive anaphylaxis in guinea pigs with the antibody of 
quinidine purpura were not successful. 
I wish to express my appreciation  to Jefferson  W. Hamby, Hospital Corpsman First Class, 
United States Navy, William G. Clutter, Hospital Corpsman First Class, United States 
Navy, and Miss Mildred L. Garrison for their assistance  in this work. 
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EXPLANATION OF PLATE 58 
FIGs. 1 A to 1 E. Criteria for grading agglutination. 
FIG.  1 A,  homogeneous  suspension  of discrete platelets with  no  agglutination; 
Fig.  1 B, 1+ agglutination,  about half the platelets aggregated  in clumps of 2 to 6; 
Fig. 1 C, 2+ agglutination,  larger dumps with few free platelets; Fig.  1 D, 3+ ag- 
glutination,  all  platelets  agglutinated  in  large  dumps  with  wide  spaces  between 
dumps; Fig. 1 E, 4+ agglutination,  very large clumps far apart. Intermediate de- 
grees of agglutination  such as  ~  or 3-4+ could be discerned.  The morphology of 
individual  platelets remained  the same in agglutinated and control mixtures.  Those 
platelets appearing less refractile in agglutinated dumps are out of focus owing to 
chamber depth. Magnification 430, bright light. 
Fig.  1 F.  Smear of endothelial  cell preparation used  in place of platelets in at- 
tempt to fix complement.  Papanicolaou  stain, 430 magnification. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  ~07  PLATE  58 
FIG.  1 
(Shulman: Immunoreactions involving platelets.  III) 